Abstract
Multimodal treatment of patients with early and advanced -stage solid tumors has been standardized leading to oncological outcome improvement. Recently, many multigene assays have been approved by the FDA for tumor genomic profiling while a few only gene panels for circulating tumor DNA (ctDNA) testing have been integrated in the treatment of advanced solid tumors. These multigene assays are widely used as predictive biomarkers to select patients for individualized treatment.rolex replica Here are discussed latest advances in patient selection to guide targeted therapy or immunotherapy with pembrolizumab, nivolumab, and atezolizumab.

(Citation: Gastric & Breast Cancer 2020; 17(1): 6-11) ysl outlet

Back

PDF Version